Price analysis and comparison of various specifications of Ixazomib/Enleri in 2024

Ixazomib, trade name: Ixazomib (Ixazomib), is a revolutionary oral treatment drug for patients with multiple myeloma (MM). As a second-generation proteasome inhibitor, it brings new treatment options to patients with its excellent efficacy and convenient oral administration. Ixazomib has received authoritative certification from the U.S. Food and Drug Administration (FDA) and is often used in combination with dexamethasone and lenalidomide to form an all-oral treatment regimen, which significantly extends the progression-free survival of patients.

From a pharmacological perspective, the core structure of ixazomib is composed of alanine and leucine dipeptides, which selectively inhibits the chymotrypsin-like activity of the 26S proteasome, thereby breaking the stable state of cancer cells and inducing apoptosis. This mechanism is not only effective on MM cells that are sensitive to conventional therapies, but also shows strong killing power against drug-resistant cells.

Ixazomib is available as oral capsules in three dosage options: 2.3mg, 3mg and 4mg. The standard treatment regimen recommends that patients take 4 mg of ixazomib on days 1, 8, and 15 of each 28-day treatment cycle. At the same time, it needs to be used in conjunction with dexamethasone and lenalidomide, and the specific medication schedule will be accurately arranged according to the treatment cycle. It is important to note that ixazomib should be taken on an empty stomach, while dexamethasone is recommended with food.

In terms of price, the original drug of ixazomib has been launched in the domestic market and has been included in the Class B medical insurance catalog, reducing the financial burden for patients. Its 4mg, 3mg and 2.5mg capsule preparations are priced at approximately more than RMB 10,000 per box. However, the price of original drugs in overseas markets is higher than that in China, and the price of a single box may climb to more than 10,000 US dollars. Fortunately, some overseas pharmaceutical factories such as Laos are also producing ixazomib. Its pharmaceutical ingredients are highly similar to the original drug, but the price is significantly more affordable. For example, the price of 4mg*3 tablets of ixazomib per box may be as low as less than RMB 1,000. Of course, the final price will also be affected by factors such as exchange rate fluctuations.